Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide
| Status: | Withdrawn |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/27/2018 |
| Start Date: | August 22, 2014 |
| End Date: | August 22, 2019 |
Pilot Study of the Identification of the Molecular Signatures of Relapse in Small Cell Lung Cancer
This pilot research trial studies molecular signatures of the return of cancer after a period
of improvement (relapse) in tissue samples from patients with small cell lung cancer who are
receiving or planning to receive cisplatin and etoposide. Studying samples of tissue from
patients with small cell lung cancer in the laboratory may help doctors learn more about the
changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer
relapse.
of improvement (relapse) in tissue samples from patients with small cell lung cancer who are
receiving or planning to receive cisplatin and etoposide. Studying samples of tissue from
patients with small cell lung cancer in the laboratory may help doctors learn more about the
changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer
relapse.
PRIMARY OBJECTIVES:
I. To collect and analyze small cell lung cancer (SCLC) tumor DNA and ribonucleic acid (RNA)
from 3 human patients before and after relapse to identify the molecular signatures of
relapse.
OUTLINE:
Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at
baseline. Patients also undergo collection of tissue samples for analysis at relapse.
I. To collect and analyze small cell lung cancer (SCLC) tumor DNA and ribonucleic acid (RNA)
from 3 human patients before and after relapse to identify the molecular signatures of
relapse.
OUTLINE:
Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at
baseline. Patients also undergo collection of tissue samples for analysis at relapse.
Inclusion Criteria:
- Any patient seen at Norris or County with histologically confirmed SCLC, with tissue
in the Norris Cancer Center Tumor Repository
- Patients must be undergoing or about to start first line treatment with cisplatin and
etoposide
- Patients may not have a second malignancy
We found this trial at
2
sites
1983 Marengo St
Los Angeles, California 90033
Los Angeles, California 90033
(323) 226-2622
Principal Investigator: Barbara J. Gitlitz
Phone: 323-865-3000
Los Angeles County-USC Medical Center The origins of LAC+USC Medical Center date back to 1878,...
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Barbara J. Gitlitz
Phone: 323-865-0514
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
Click here to add this to my saved trials